Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Wai Conrad, CEO of Counterpart Health (NASDAQ:CLOV), sold 15203 shares of Class A Common Stock on July 8, 2025, at prices ranging from $3.25 to $3.27, netting $49561. The sale occurred as CLOV trades at $3.04, with the stock showing significant volatility and a remarkable 127% return over the past year.
According to a Form 4/A filing with the Securities and Exchange Commission, the transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 3, 2025. Following the sale, Wai directly holds 1613498 shares. InvestingPro analysis reveals the company’s strong financial health score of 3.26, with analysts setting price targets ranging from $3.75 to $6.00.
On September 13, 2024, Wai also acquired 379866 shares of Class A Common Stock. These shares represent restricted stock units earned in connection with performance achievements related to a grant awarded on October 31, 2023. One-half of the earned restricted stock units vested and were settled on September 13, 2024, and the remaining one-half of the restricted stock units will vest on October 31, 2025, subject to continued employment. The company, currently valued at $1.54 billion, has shown strong momentum with a 19% gain in the past week.
In other recent news, Clover Health Investments Corp reported strong financial results for the first quarter of 2025, with a 33% increase in revenue totaling $457 million. The company also saw a 30% growth in Medicare Advantage membership. Adjusted EBITDA rose significantly by 279% year-over-year, and Clover Health ended the quarter with $391 million in cash and investments. The company has raised its full-year 2025 guidance, expecting insurance revenue to be between $1.8 billion and $1.875 billion. Meanwhile, Clover Health has taken steps to enhance shareholder communication by addressing investor queries through a shareholder Q&A. The company continues to emphasize its commitment to transparency and active investor relations. Additionally, Clover Health has successfully repurchased 5 million shares of common stock, reflecting confidence in its long-term value. Analyst firms have noted the company’s strategic initiatives and increased guidance, highlighting Clover Health’s optimistic financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.